Celltrion Announces FDA Oncologic Drugs Advisory Committee Meeting Schedule for Proposed Biosimilar to Rituxan® (Rituximab)
Celltrion, Inc. (KRX:068270) today announced that the U.S. Food and Drug Administration (FDA) has scheduled the Biologics License Application (BLA) for CT-P10, a proposed monoclonal Antibody (mAb) biosimilar to Rituxan®1 (rituximab), for discussion by the Oncologic Drugs Advisory Committee (ODAC) on October 10, 2018. Rituxan® is a Biogen and Genentech USA, Inc.’s rituximab product.
The ODAC reviews and evaluates data concerning the safety and effectiveness of investigational human drug products for use in the treatment of cancer and makes recommendations to the FDA.
“We are fully committed to preparing for this advisory committee meeting and look forward to the discussion about CT-P10,” said Woosung Kee, Chief Executive Officer of Celltrion. “The development of biosimilars is of great importance in the field of oncology, and has the potential to enrich our therapeutic arsenal and to increase accessibility to therapies for patients at an affordable price.”
Celltrion and Teva Pharmaceutical Industries, Ltd. entered into an exclusive partnership to commercialize CT-P10 in the U.S. and Canada in October 2016.
1 Rituxan® is a registered trademark of Biogen and Genentech USA, Inc.
Celltrion’s CT-P10, a proposed biosimilar to Biogen and Genentech USA, Inc.’s Rituxan®, is currently approved in more than 47 countries across the globe. CT-P10 is the world’s first monoclonal antibody (mAb) biosimilar approved by the European Commission (EC) for the treatment of oncology and launched in Europe in 2017. The final U.S. prescribing information for CT-P10 will include the specific uses for which the product is indicated in the U.S. Rituximab, the active substance in CT-P10, has been designed to bind specifically to the transmembrane protein CD20 found on both malignant and normal B cells.
About Celltrion, Inc.
Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacturing of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and EC’s approval for INFLECTRA® and Remsima®, respectively, which is the world’s first mAb biosimilar to receive approval from a regulatory agency in a developed country. For more information, visit www.celltrion.com.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Pacific Drilling Successfully Emerges from Chapter 11 Proceedings19.11.2018 20:18 | Pressemelding
Pacific Drilling S.A. (OTC: PACDQ) (the “Company”) announced that effective today the Company and certain of its affiliated chapter 11 debtors have emerged from bankruptcy after successfully completing restructuring transactions pursuant to their chapter 11 plan of reorganization (the “Plan”). In connection with emergence from bankruptcy, the Company raised $1.5 billion in gross proceeds in new capital, consisting of $1.0 billion of new secured notes and $500 million of equity. Pursuant to the Plan, the Company equitized approximately $1.85 billion in pre-petition debt associated with the Company’s Term Loan B, 2017 Notes and 2020 Notes, and paid in full approximately $1.2 billion of debt related to its pre-petition senior secured credit facility, revolving credit facility and the post-petition debtor-in-possession financing. Customer, employee and ordinary trade claims were unimpaired. The Plan has strengthened the Company’s balance sheet by significantly reducing its leverage and enh
Tempo Announces New Majority Ownership by Diversis Capital19.11.2018 20:10 | Pressemelding
Tempo, a leader in productivity-enhancing project management solutions, today welcomes Diversis Capital as a new strategic owner with a controlling interest in the company. Former owner and founder, Origo, will retain a 45% stake in Tempo, and remains an important partner. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181119005782/en/ “We are very pleased to announce new ownership by Diversis Capital with their wide experience of working with unique tech companies and the tremendous opportunity for growth that this brings,” said Agust Einarsson, CEO of Tempo. “Diversis has demonstrated their value to investments through its collaborative approach using their operating partner and strategic advisors working alongside management to take companies to the next level. Additional financial support will lend further strength to Tempo’s global growth.” Created in 2007 as an internal tool to track time utilization and management on
Valence Advises Golden Gate on Acquisition of Active Minerals19.11.2018 19:07 | Pressemelding
The Valence Group acted as financial advisor to Golden Gate Capital on its announced acquisition of Active Minerals International from Merit Capital Partners. Financial terms of the transaction were not disclosed. About Active Minerals International Active Minerals International LLC (AMI) is a worldwide leader in the production and marketing of kaolin and gel quality attapulgite clay minerals. Its products are sold throughout the world for industrial, agricultural and construction related applications. AMI is the world’s largest supplier of gel quality attapulgite (clay) and is the largest supplier of air-float kaolin to the glass manufacturing process. About Golden Gate Capital Golden Gate Capital is a San Francisco-based private equity investment firm with over $15 billion of capital under management. The principals of Golden Gate Capital have a long and successful history of investing across a wide range of industries and transaction types, including going-privates, corporate divest
Moody’s Analytics Earns #4 Spot in 2019 Chartis RiskTech100®19.11.2018 16:45 | Pressemelding
Moody’s Analytics, a global provider of financial intelligence, has been ranked #4 in the 2019 Chartis RiskTech100®, our best-ever finish. We also won awards in the Strategy category and in five solution categories: CECL, IFRS 9, Balance Sheet Risk Management, Credit Risk for the Banking Book, and Model Validation. This year, Moody’s Analytics earned a category award in one of the overall Chartis categories, Strategy, which considered our ability to execute, our vision and leadership, and our financial performance. Click here for more on our solution category wins. Now in its 13th year, the RiskTech100® evaluates technology companies that provide risk and compliance solutions to financial institutions. Moody’s Analytics has finished in the top five of these rankings for three straight years. “Moody’s Analytics continues to help its clients across the globe to satisfy their risk technology needs,” said Rob Stubbs, Head of Research at Chartis Research. “The breadth of its offerings is re
Moody’s Analytics Wins Five Solution Category Awards in 2019 Chartis RiskTech100®19.11.2018 16:45 | Pressemelding
Moody’s Analytics, a global provider of financial intelligence, has won five solution category awards in the 2019 Chartis RiskTech100®: CECL, IFRS 9, Balance Sheet Risk Management, Credit Risk for the Banking Book, and Model Validation. We also earned the #4 overall ranking – our highest-ever position and third straight top-five finish – and took the award in the Chartis Strategy category. Click here for more on our ranking and Chartis category win. “We’re honored by the recognition we received in this year’s RiskTech100®,” said Jacob Grotta, Managing Director-Head of Risk & Finance Analytics. “Winning five categories demonstrates that our solutions are empowering financial professionals across the lending, risk, and finance functions to make better, faster decisions.” We have now won the Credit Risk category for three straight years, reflecting both our deep credit experience and our continued investment and innovation in our wholesale and consumer credit assessment and origination so
Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares19.11.2018 16:30 | Pressemelding
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) (“Axonics”), a medical technology company focused on the design, development and commercialization of innovative and minimally invasive sacral neuromodulation (“SNM”) solutions for the treatment of overactive bladder (“OAB”), fecal incontinence (“FI”), and urinary retention (“UR”), today announced that the underwriters of its initial public offering exercised in full their option to purchase an additional 1,200,000 shares of common stock from Axonics at the initial public offering price of $15.00 per share, less underwriting discounts and commissions. With this exercise, the total number of shares of common stock sold by Axonics in the offering increased to 9,200,000 shares, representing total gross proceeds of $138 million, before underwriting discounts and commissions and offering expenses. Axonics’ common stock began trading on The Nasdaq Global Select Market under the ticker symbol “AXNX” on October 31, 2018. BofA Merrill Lynch a